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Introduction 
Peripheral vascular disease (PVD) is the third leading cause of cardiovascular morbidity with a global burden of over 200 million affected individuals [1]. 
Despite prevalent myth that this disease is confined solely to high income countries it is rather a disease process with worldwide impact [2]. As the incidence 
of diabetes mellitus, smoking, and increasing age rise globaly there will continue to be an incruase in the incidence of PVD [2,3]. 
The economic burden is significant.In the United States alone, PVD accounts for over $20 billion in annual healthcare related costs [4]. Non-heeling wounds 
represent a significant portion of this expenditure with the total cost estimate at more than $3 billion per year [5]. Wound care and 1N0und prevention account 
for much of this direct cost. More difficult to measure are the indirect costs to the individual and society. This economic burden is only likely to increase in the 
next twenty yaers. Population studies project that the percentage of individuals over the age of 65 will double in the United States [6]. Escalating the problem 
further is the projection that the percentage of diabetes in that population will also increase [7]. Both age and diabetes are known dominant risk factors not 
only for the development of PVD but also that of PVD related tissue loss and 1N0unds. 
While PVD encompasses both arterial and venous disease processes, this review focuses specifically on the 1N0unds associated with peripheral arterial 
disease (PAD). Arterial disease leading to tissue loss and chronic ulceration is estimated to effect 100,000 individuals in the United States annually [B]. PAD 
is often asymptomatic but its most common presentation is intermittent claudication, pain in the muscle of the leg with ambulation that is quickly relieved with 
rest [9]. Claud I cation rarely progresses to lower extremity wounds and therefore does not require urgent In llne flow restoration [1 O]. 
A more significant degree of PAD is characterized by critical limb ischemia (CLI). CLI encompasses rest pain, continuous lower extremity pain most 
commonly in the feet secondary to severe PAD and tissue loss.The tissue loss is a progression from the rest pain and results in skin ulceration and gangrene, 
the source of PAD-induced wounds [3,9]. The incidence of CLI is 500 to 1000 new cases per million patients in Western society [3]. These patients carry high 
rates of limb loss and death within the next year so aggressive care of their disease and wounds is imperative and requires urgent arterial in flow restoration to 
heal lower extremity vwounds [3,9]. 
This paper reviews the pathophysiology of PAD and its association with wound development. We summarize the current therapy available to improve PAO.­
induce vwounds and present the active research in this field that may lead to new treatmerrts. Finally, we review how the use of a team-based approach is 
necessary for treatment and provide the best outcomes for the patients. 
Pathophysiology 
Normal 1N0und healing consists of regulated and integrated phases: hemostasis, inflammation, proliferation and tissue remodelling [11]. Oxygen plays a central 
role in each step of the healing process. PAD interrupts this normal process by creating a system of localized hypoxia. Despite their limitations, mathematical 
models have demonstrated the importance of oxygen for nonnal physiologic wound healing [12]. Initially hypoxia initiates the inflammatory step of vwound 
healing by boosting reactive oxygen species activity, which in tum further activates platelets and induces cytokine release [13]. Chronic, however can impair 
proliferation by decreasing neo-engiogenesis [14]. Further tissue remodeling is dramatically affected by the concentration of oxygen. In this phase, we see the 
differentiation of fibroblasts to contractile myofibroblasts triggered specifically by oxygen and mediated by Transforming Growth Factor- ~1 (TGF~1), 
Transforming Growth Factor-~ (TGF-~), and Platelet Derived Growth Factor (POOF) [15, 16]. As healing progresses the initial type Ill collagen is replaced by 
the more permanent type I collagen, which is mediated in an oxygen dependent fashion by fibroblasts [16, 17] (Figure 1). 
PAD has Its effects on the local wound environment by macrovascular and mlcrovascular processes. Macrovascular disease Is the sequelae of 
atherosclerosis on larger axial vessels. The earliest vascular change here begins with intimal thickening which consists of increased smooth muscle cells and 
abnormal deposits of extracellular matrix within the tissue [18]. Initially, blood flow is minimally affected but as the disease progresses there is increased 
disruption of flow and consequently the creation of an lschemlc environment [19]. Unllke ulceration from venous Insufficiency, where disease usually artses In 
the distal leg or so called "gaiter" regsions, arterial leg wounds typically affect the forefoot or toes, though wounds presentat any spot distal to the arterial 
perfusion abnormality may suffer from non-healing regardless of original etiology. 
A compounding factor common in PAD patients is the effect of compromised mobility on their disease process [20]. Diminished mobility can lead to prolonged 
periods of unrelieved pressure on the extremities resulting in increased shearing force applied to the skin and underlying tissues leading to a decrease in 
oxygen tension and eventual tissue necrosis. 
Chronic wounds have several key phenotypic differences as compared to acute wounds. They have a lower concentration of growth factor receptors as well as 
lower mitogenic potential, which prevents normal response to physiologic stimuli.Fibroblasts isolated from patients with PVD and diabetes have abnormal 
responses to Insulin Growth Factor (IGF), Platelet Derived Growth Factors - A&B (PDGF-A,B),and Basic Fibroblast Growth Factor (bFGF) applied either in 
combination or alone [21-23]. Fibroblasts in the ischemic tissues of PAD have decreased mobility resulting in poor granulation of the wound bed [24]. 
The underlying molecular and cellular pathways in PAD are complex and to dale not fully understood, but great strides have been made in diabetes mellitus­
induced PAD. Diabetes mellitus acts synergistically to accelerate PAD. Diabetes through the effect of hyperglycemia on the acceleration of atherosclerosis 
increases this process while also preferentially targeting distal vascular beds [24,25]. Endothelial dysfunction and progression of both micro and macro 
vascular disease in the diabetic population seems to be mediated by decrease in nitric oxide (NO) bioavailability. Hyperglycemia blocks the activity of 
endothelial NO synthase and thereby increases the number of reactive oxygen species causing damage at a microvascular level [26]. Insulin resistance at the 
cellular level leads to increased free fatty acids, which can cause further oxidative damage and activation of proinflammatory pathways such as the mitogen­
activated protein kinase pathway [27]. The effects of diabetes mellitus appear to be very earty in the disease process with the rates of PAD being similar 
between pre-diabetic and diabetic patients [28]. Genetics is also important with patient with relatives with PAD have a two-fold increase in PAD regardless of 
other disease conditions [29]. While many aspects of vascular and wound physiology are yet to be fully understood, current therapy seeks to increase 
perfusion and decreased localized hypoxemia to heal ischemia-induced wounds. While there is still considerable work to understand the molecular basis for 
PAD and its progression to tissue gangrene and wounds, the pathways currently understood serve as the basis for the current translational research. This work 
exemplifies the need for our current treatment strategies to reduce risk factors and restore perfusion as well as the need for newer therapeutic modalities. 
Current Standards in Therapy 
Arterial disease-induced IOYie!" extremity wounds have inadequate perfusion therefore restoring arterial inflow to the extremity is the primary goal of all current 
therapy [30]. There are three major avenues to improve vascular perfusion: medical management, open surgery, and endovascular surgery. 
Medic:.I management 
Patients with PAD also have a high rate of coronary arterial disease (28-94%) and increased risk of stroke (twice no~AD patients) [31,32]. Therefore lifestyle 
modification and medical management of peripheral arterial disease and the associated risk factors such as smoking, diabetes mellitus, hypertipidemia, 
hypertension, and hypercoagulability, are indicated for all patients with PAD. Smoking cessation is vital for patients with peripheral vascular disease as the 
association between smoking and development of PAD is greater than with coronary artery disease.Active smokers have an odds ratio for PAD of 2.67 
compared to non-smokers that decreases to 1.67 in former smokers.While the risk of PAD does not go to non-smoker levels it does decrease and therefore 
aggressive smoking cessation Is required [33,34]. Supervised exercise programs Improved walklng distances In claudlcants with PAD [34-36]. Hypertlpldemla 
control with slatins has been demonstrated to improve limb salvage rate in critical limb ischemia [37,38]. Strict glucose management after intervention is also 
associated with improved limb preservation [39]. Anti-platelet agents have not been individually demonstrated to improve limb salvage, however, aspirin has 
been shown to marglnally Improve llmb survlval after bypass surgery [40]. When patients with pertpheral artertal disease stop smoking, and adhere to a statln, 
aspirin, and angiotensin converting enzyme inhibitor therapy there is a significant improvement in major limb adverse events [41]. Medical management of 
PAD involves significant lifestyle modifications, but when implemented there can be drastic improvements in PAD symptoms as well as progression of the 
disease [34]. 
Cilostazol, a phosphodiesterase-3 inhibitor, is frequently used in patients with claudication for its vasodilatory and anti-platelet actions.Cilostazol has also 
been shown to improve skin perfusion pressure in severely ischemic limbs [42]. The use of cilostazol, after angioplastyon critically ischemic limbs, has also 
demonstrated improvement in amputation-free survival, reduced restenosis, and reduced re-intervention rate [43-45]. Recently a small clinical trial has 
demonstrated the potential for improvement in ischemia-induced wounds with the combination of clopidogrel and cilostazol in patients who are not candidates 
for any intervention to improve perfusion [46]. 
Surglcal therapy 
While advances have been made in the medical management of lower extremity ischemia-induced wounds, large arterial revascularization remains the current 
standard of care.Open bypass surgery is often employed to bypass stenotic arteries and improve perfusion to lower extremity wounds with one-year patency 
reported to be over 80% for more proximal bypasses [30,47]. Distal landing zones for bypasses often are the popliteal, tibial, and peroneal arteries. However, 
when required, bypass grafts onto the pedal vessels have been shown to be feasible with 67% of the patients being able to still ambulate at three years [48]. 
Autologous vein is the optimal material for lower extremity bypass grafts [49]. Specifically the greater saphenous vein is the conduit of choice, but if not 
available arm or short saphenous vein may be used with foot preservation rates of 75% at 5 years [50]. When autologous vein is not available other 
alternatives include sytheteic materials such as Dacron, polyteratluoroethylene (PTFE), cryo-preserved allograft veins, and deep calf vein arterialization with 
less degrees of patency [51-55]. Hlstortcally, the healthlest avallable tlblal artery has been used as a target for bypass In crttlcal llmb lschemla, but current 
research is demonstrating that use of the angiosome model, which involves bypass to the specific tibial artery that is known to distribute blood to the specific 
wound location may be a more effective strategy [55,56]. 
Endovuc:ular surgery 
Over the last two decades, endovascular intervention has emerged as an additional therapy to improve perfusion to ischemia-induced wounds.This therapy 
has grown exponentlally as It Is mlnlmally Invasive, may have lower associated morbidity and mortallty, and Is practiced across multlple speclaltles. It Is 
associated with lower primary patency than surgical revascularization, but may have comparable limb salvage rates [30,57]. The technical aspects and 
success of this therapy is constantly changing as new technology continues to emerge.It has been shown to be successful in limb preservation even with 
below-the-l<nee procedures and newer technology to address even small tibial vessels with endovasculartherapy continues to evolve [58-60]. 
The diabetic PAD patient Is classlcally been difficult to treat v.1th high rates of death and major amputations, but recently endovascular therapy has emerged 
as effective treatment for diabetic ulcers (61- 63). Rates of diabetic ulcer healing have neared 60% with complete healing near 45% after lower extremity 
endovascular therapy [63]. In this population, the presence of obesity was associated with poor outcomes from the procedure [62]. Elevated Creactive protein 
and being currently on hemodialysis were associated with non-healing or reoccurrence of the ulcers [62,63]. While still not perfect, endovascular therapy is 
showing prnmise in diabetic PAD patients. 
Efficacy and safety of endovascular therapy and open surgery are often compared [30). Many trials have established the limb salvage rate of both open 
surgery and endovascular to be similar with one year limb salvage rates around 88% [49,64]. Mortality and amputation rate are similar between both 
modalities, but major adverse limb events were seen following endovascular procedures [49]. In specific populations, such as the extremely elderly or in those 
with significant cornorbidities, endovascular therapy has been shown to be superior largely due to its lower peri-operative mortality and morbidity (65,66). With 
good data to support the use of both open and endovascular therapy one therapy cannot be deemed superior to the other. Many factors such as anatomy, 
patient condition, prior surgeries, as well as the practitioners' comfort level should be used in selecting the modality of therapy to utilize [49]. 
Local wound care 
In addition to improved perfusion of lower extremity wounds, local wound care is required to expedite the healing process and prevent infection.Several 
treatments are implemented for wound care and include mechanical debridement, enzymatic debridement, tissue protection, and hyperbaric oxygen therapy 
[30,67]. While many methods and therapies are employed for debridement and protection most are without supporting evidence-based research [68]. While the 
data is sparse there are several trials looking at topical treatment of wounds (Table 1). Hyperbaric oxygen therapy is becoming increasingly used for the local 
care of non-healing wounds.In diabetics with critical limb ischemia, hyperbaric oxygen may prnmote wound healing, but overall one year amputation-free 
survival rate remains unchanged demonstrating that this therapy may help the wound but not the source of the problem [45,67]. 
Amputation 
Ultimately, if local wound care and restoration of arterial perfusion fails to heal lower extremity wounds, amputation becomes necessary. There are multiple 
factors that contribute to cr1tlcal wound lschemla prggresslng to amputation. These Include diabetes mellltus, hypertension, renal Insufficiency, elevated body 
mass index, active smoking, age, and hyperlipidemia [64,69). Unfortunately, only 48- 75% of those who prggress to amputation had prior re-vascularization 
attempts one year before amputation [30,69]. Therefore 'Ml are not maximizing our current therapeutic options.All reasonable attempts to preserve these limbs 
should be made as once a patient has at least one below knee amputation they are more likely to have a contralateral amputation and an earlier mortality (69). 
There is significant cost to the care of peripheral arterial-induced lower extremity wounds.The amount of resources and money has been challenged in the 
literature [70], but recent research has demonstrated that aggressive revascularization may lead to healthcare cost savings compared to local wound care and 
even amputation [71]. These cost savings were even noted in high-risk individuals with end stage renal disease. In these patients, there was significant cost 
savings (although marginal health improvement) in those who underwent revascularization compared to amputation and wound care alone (72). 
The standan::I of care for patients with lower extremity wounds secondary to ischemia should be revascularization with local wound care as an adjunct but not 
monotherapy whenever possible. However we are not reaching every patient who could benefit from revascularization. In addition the current standards in 
treatment are limited and do not entirely improve distal wounds or prevent amputation. Therefore novel techniques that can improve the overall outcomes and 
potentially reduce cost are necessary. For this reason the current research being conducted on PAD is vital to improve the treatment of PAD-induced wounds. 
Current Research 
While new technology may lead to slight improvements in outcomes, the greatest improvements in arterial-induced wound care may come from the 
bench.Current translational research for the treatment of peripheral arterial disease and subsequent lower extremity wounds focuses on improving perfusion 
thrnugh therapeutic angiogenesis. These areas include gene therapy for angiogenesis, stem cell induction of angiogenesis, and microRNA regulation of 
angiogenesis. 
Gane therapy 
Gene therapy in vascular disease uses recombinant protein or genes for angiogenic growth factors that are used with the intent of increasing collateral 
circulation and enhanced perfusion to the ischemic tissues of arterial diseased-induced wounds [73). Clinical trials have attempted multiple forms of delivery 
including viruses, plasmids and both intra-arterial and intra-muscular injections [74]. The greatest success in delivery of pro-angiogenic genes to ischemic 
tissue has been with adenovirus-based vectors, but due to the ease of administration intramuscular injections of vectors is the most commonly used in clinical 
trials [73,75). The pro-e.ngiogenic factors that have been studied as potential targets include: vascular endothelial growth factor (VEGF), fibroblast growth 
factor (FGF), hypoxia-inducible factor 1 (HIF-1), hepalocyte growth factor (HGF), and developmentally regulated endothelial cell locus-1 (Del-1) (73-79]. All 
have been shown to have efficacy in pre-clinical rodent models and been shown to be safe in phase I trials, but have had mixed results in phase II efficacy 
trials [75- 77]. 
The most widely studied gene to date has been VEGF, which is known to regulate vascular growth, increase vascular permeability, and mediates angiogenesis 
[77]. VEGF gene therapy with both plasmid and viral vectors has been shown to increase collaterals and tissue perfusion in rodent models (78,79]. Results of 
these trials have demonstrated improvement in collateral circulation and subjective improvement, but they have failed to show objective results in heeling 
ulcers, preventing amputations, improving walking lime, improving claudicalion, or increasing ankle-brachia! indexes (ABls) [74,78]. Several PAD clinical trials 
reported increased lower extremity edema after VEGF gene therapy treatment [74,78,79]. Of the three phase II clinical trials conducted, only one showed 
positive results with increased vascularity, which has been questioned to be a reliable endpoint [73]. 
The only phase Ill clinical trial of gene therapy conducted for PAD has been with FGF-1, which modulates prnliferation and migration of several cell types vital 
for angiogenesis [77]. This study was conducted after a phase II trial had shown prnmise for improved ulcer healing and reduced amputation rate by four serial 
doses of intra-muscular injections of FGF-1 plasmid [75,77]. The phase Ill trial failed to demonstrate any efficacy in amputation rate or ulcer healing and 
hence this has not been approved for routine use [75,77]. 
While pre-clinical research has shown promise in gene therapy for improving perfusion in critical limb ischemia, the clinical trial data is mixed at best.Hammer 
et al. conducted a meta-analysis on 12 randomized-<:ontrolled clinical trials of gene therapy for PAD and concluded that gene therapy was safe and well 
tolerated. When they evaluated the efficacy of gene therapy they concluded there was no significant improvement in all-<:ause mortality, amputation rate, and 
ulcer healing with the use of gene therapy compared to controls [76). Certainly further research both in the lab and in the form of clinical trials is required 
before this therapeutic approach can be used rnutinely. 
Cell-based therapy 
Cell-based therapy Involves the Introduction of progenitor cells that have the potential to Initiate vasculogensls or post-natal anglogenesls, which Is the 
development of new vessels from endothelial progenitor cells that differentiate and mature into new vessels (77]. These endothelial progenitor cells are thought 
to ralease pro-angiogenic factors that mediate a paracrine effect on the surrounding local environment [74]. Cells that ara being evaluated for potential therapy 
Include endothelial progenitor cells (EPCs), bone marrow mononuclear cells (BM-MNCs), mesenchymal stem cells (MSCs), adipose-derived stem cells 
(ADSCs), human embryonic stem cells from cord blood (hESCs), and induced pluripotent stem cells QPSCs) [74,77,80-85]. In addition to specific cell 
transplantation, stem cell-stimulating cylokines such as granuclcyte macrophage-colony-stimulating factor (GM-CSF) era employed to upragulate existing 
stem cells in ischemic tissues (77]. 
EPCs are derived from the peripheral blood and can be found within tissues as well [83]. EPCs are involved in the creation of new capillaries and secretion of 
cytokines that induces other endothelial cells to proliferate with in the ischemic tissue [77,83]. In most critically ill patients such as those 1Nith critical limb 
ischemia, circulating progenitor cells are rara. Therefora, EPCs are derived from stimulated (1Nith GM-CSF) bone marrow or ex vivo expansion of EPCs of 
circulating progenitor cells with differing degrees of selection based on their cellsurface antigens [77,82]. Studies of GM-CSF as a monotherapy in PAD to 
increase circulating EPCs for critical limb ischemia have failed to show significant clinical improvement in patients. However one trial showed improved 
walking time [82]. Early trials of GM-CSF of efficacy have shown improvement in exercise capacity, ulcer healing, ABls, toe brachia! prassure index, and 
tissue oxygenation [74, 77,83]. 
BM-MNCs are derived from bone marrow aspirates that are centrifuged to obtain several types of multipotency stem cells that serve as hematopoietic stem 
cells [77]. Animal trials demonstrated increased neovascularization in ischemic limbs which lead to clinical trials [77]. Cinical trials on CU demonstrated the 
injection of BM-MNCs to be safe in comparison to controls and improvement in ulcer healing, amputation-free surivial, rest pain, ABls, and tissue oxygen 
pressure [74, 77,82]. Administration of the BM-MNCs has mostly been intramuscular, but one trial with intra-arterial injection did demonstrate improved wound 
healing and demonstrated improved efficacy after repeated doses [74,82]. BM-MNCs when comparad to non-mobilized peripheral MNC demonstrated 
improvedABls and rest pain showing a greater EPC fraction available from the bone marrow [82]. 
MSCs are derived from bone marrow as wen, but are not hematopoetic in nature [77,85]. These cells have created great interest because of their ease of 
isolation, lack of immunogenicity, ease of modification with specific genes, ablility to expand ex vivo, and safety of systemic or local delivery [74,77,80,81]. 
The mechanism of action for these cells is strictly through ralease of cytokines that induce endothelial cells to proliferate and differantiate into new vessels 
[77,85]. Therefore many of the clinical trials thus far have used these cells in combination with other cell lines such as EPC and BM-MNCs. In combination 
with BM-MNCs, MSCs have shown improvements in rest pain, exercise tolerance, ABls, tissue oxygen pressure, and collateralization [77]. In a head-to-head 
comparison of BM-MNC and MSCs the rate of diabetic foot ulcers in CU was noted to be faster as well as improved tissue oxygenation and improved walking 
distance with MSCs[74]. Allogeneic MSCs derived from healthy donors injected intramuscularly in to ischemic lower extremities have been demonstrated to 
be safe and trended toward improved ABls (81]. Allogeneic umbilical cord blood MSCs have also recently studied to be safe for patients with CU [80]. Cell 
therapy holds great promise for future treatment of lower extremity wounds secondary to PAD. 
The work in cell therapy has occurred concomitant with the progress in gene therapy.One could surmise that thera may be an incraased effectiveness by 
combining these two therapies.While this has not reached human trials, work in animals has shown promise in improved perfusion in in PAD with the 
combined gene and cell therapies of HGF and BM-MSCs, respectively improving perfusion in ischemic rodent limbs (86]. While still removed from human trials 
these early advances show promise lo overcome the currant disappointing results of the currant monotherapy trials. 
mlcroRNA therapy 
microRNA (miRNA) therapy is one of the newest araas of rasearch in treating critical limb ischemia with tissue loss. While these noncoding pieces of RNA 
were only discovered a little over two decades ago they have been found to have significant roles In many blologlcal functions Including anglogenesls and 
wound healing [87]. miRNAs are found virtually in all tissues and bind to specific post-transcriptional mRNA causing gene silencing through inhibition of 
translation and eventual degradation of the mRNA [88]. Each miRNA has multiple mRNA which it binds to and alters their translation in addition the exprassion 
of mRNA Is different between tissues and states of tissues [87-89]. When tissues are In a hypoxic state a subset of mlRNAs are Induced or Increased In 
expression that ara known as hypoxamiRs [88]. 
HypoxamiRs are up-regulated in ischemic tissues.A portion of hypoxamiRs may be in fact known to be inhibitory lo tissue repair, but another subpopulation 
appears to promote tissue repair and some angiogenesis and hence have been termed angiomiRs [90]. Current research is establishing whether each altered 
miRNA is beneficial or detrimental to wound healing.HypoximRs appear to be involved 1Nith regulation of inflammation, control of redox reaction, angiogenesis, 
and tissue rapair [87,91]. The presence of hypoxamiRs appears to alter the response of certain cells, specifically endothelial cells to ischemia specifically by 
allowing the production of reactive oxygen species to promote angiogenesis [92]. Some miRNA that are down-regulated during ischemia appear in normal 
tissue to inhibit angiogenesis and other forms of tissue repair, but during hypoxia are lost and allow cellular regeneration machinery to function in repair of the 
cell such as VEGF, hypoxia-inducible factor (HIF) and metalloproteinase-9 (MMP- 9) [91,93]. Two specific miRNAs that have been identified in hypoxic tissues 
are miR-21 and miR-210.The presence of both of these miRNA within the wound hinders the wound's healing.Stragies to downregulate both of these miRNA 
may aid in wound healing [88]. While still in pre-clinical research hypoxamiRs are interesting potential therapies for ischemia-induced wounds in that the 
molecule is relatively stable for delivery and has the potential to effect multiple gene exprassions resulting in an amplification of action (87]. HypoximR therapy 
may even be used to alter bone marrow vascular stem-cell populations to allow for up regulation and better utilization of these cells in patient predisposed to 
ischemic wounds such as diabetic patients [94]. 
AngiomiRs are a subpopulation of beneficial hypoxamiRs that appear to promote angiogenesis and are of graat interest for the treatment of ischemia-induced 
wounds [90,93]. These miRNA appear to regulate key genes in angiogenesis such as VEGF, Ephrin-A3, IGF- 1, Thrombospondin-1 (TSP-1) and others (95]. 
AngiomiRs appear to regulate several aspects of angiogenesis including proliferation, migration, and morphogenesis of endothelial cells [90]. In fact, progenitor 
bone marrow cells, which are known to induce angiogenesis in hypoxic tissue, have been shown to express and even secret angiomiRs [96]. miR-126 is a 
specific angiomiR with therapeutic potential as it is specific to endothelial cells and has been shown to promote vascular integrity and induce angiogenesis 
[90]. The introduction of miRrnimics or miR-vectors containing miR-126 into ischemic wounds have the potential to promote microvascular production and 
wound healing. The potential to target multiple aspects of angiogenesis makes angiomiRs intriguing new therapeutics, but their use will have to be carafully 
evaluated as they have the potential to induce angiogenesis in un-idenified tumors and the side-effects of the miRNA inhibitors and mimics systemically is 
unknown [89,90,95]. 
Active clinical bials 
A majority of active clinical trials in PAD-induced wound treatment are expanding upon the evolving translational research. The active clinical trials are 
focusing on the use of autogenous stem cells for neovascularization of limbs with critical ischemia.The source of stem cells ranges from bone marrow 
pluripontent stem cells to circulating monocyles and tissue-gpecific multipotent stem cells [97]. 
Medical therapies currently under Investigation Include reevaluation of the classic anti-platelet drugs such as aspirin and clopldogrel as well as several more 
non-<:onventional medications such as llprost and urokinase.One study has theorized that high hematocrits create increased blood viscosity which hinders 
perfusion in ischemic limbs with existing wounds therefore patients are being enrolled for controlled phlebolomies lo aid in IDMr extremity wound healing [97]. 
Trials for endovascular therapy are evaluating the use of new technology including laser-atherectomy devices, drug eluting stents for below knee interventions 
and the use of drug-<:oated angioplasty balloons. Open surgical clinical trials are less prevalent as the techniques are more mature, but there are ongoing 
evaluations of the patency of a variety of vascular grafts.Two trials are comparing the efficacy of endovascular intervention versus open surgery for restoring 
perfusing to critically ischemic limbs. One is evaluating approaches based upon clinical sffectiveness while the other is look at this from cost-savings 
perspective [97]. 
This research may lead to exciting new therapeutic modalities for the treatment of PAD-induced wounds in the future.As these new discoveries and 
technologies are added to our current armamentarium multiple specialists will be required for the most effective utilization. Hence, the need to for PAD wound 
team. 
Team-Centered Therapy 
With the complexity of available therapies the treatment of non-healing chronic wounds attributed to PAD requires complex surveillance, evaluation, and 
treatment from a broad spectrum of healthcare practitioners. It has been recognized since the 1980s that a 'team' approach to this subset of patients with 
vascular wounds can provide improved care [98]. Further, having a diversity of expert opinion involved in each patient's care can help offset the challenges 
posed by the multitude of therapeutic options. This becomes critical given the widespread recognition ofneed to 'save life and limb'while having a lack of 
consensus and scarce evidence in the literature regarding the superiority of one method over another [99]. 
This challenge has led to the creation of comprehensive and systems based approaches to PAD related wounds. This team approach requires not only 
dedicated and specialized personnel, but also a financial commitment on the part of the health system [100]. While financial considerationsare important, first 
and foremost a commitment to a limb salvage program by a cross section of medical practitioners is requisite. At this time a multidisciplinary focus is critical 
as there is no single health care specialty which adequately houses the expertise and experience to provide comprehensive care for these varied wounds. 
When multiple specialties are invested in the creation of a dedicated wound care center there can be a greater than 50% reduction in amputation rates and 
subsequent wound related mortality [100-105]. The diversity and complexity of the health care team is reftected in the breadth of confounding variables in PAD 
related wounds including medical comorbidities, mobility limitations, and incompletely understood molecular pathways, and multiple often non-vascular 
etiologies of wounds. 
The team must have a leader: a physician or surgeon who has a passionate focus on the development of a wound center and program. Critical team members 
can then be drafted to attain appropriate expertise. Many models have focused on the combined sfforts of specialists in vascular and pediatric surgery [106]. 
These specialists combine knowledge of revascularization as well as lower extremity physical mechanics in the goal of limb salvage. While the medical and 
surgical expertise of these specialists is necessary, it is not adequate in the provision of wound care. Dedicated and specialized nursing staff who can help 
stream line the time intensive process of both in-patient and out-patient wound care and allow for successful transition between these two patient care realms 
are important. The role of social workers in wound care is often underestimated. Patients who suffer from PAD related wounds are many times found within a 
low socioeconomic class [107]. Patients with PAD related wounds will not have the optimal chance af success without the appropriate access to resources 
such as transportation and dressing supplies. 
This expertise and dedication to patient care is associated with significant costs. At present the largest portion of direct costs is facility related fees which 
make up roughly 30% of annual expenditures [108]. With the present uncertainty regarding health care reimbursements and shifting compensation In Medicare 
and Medicaid the establishment of a wound care center does not guarantee a robust financial outcome. Indeed, most outpatient wound centers collect less 
than 40% of billable charges [108]. However, health care system revenue is offset by referrals to specialists as \Wiii as downstream revenue.The economics 
of Individual health care systems are obviously a local concern. However, from aglobal standpoint.studies examining the economics of amputation have 
demonstrated that a reduction in amputation rates yields reduced total costs to the healthcare system as well as improved quality af life metrics for our 
patients [109, 110]. 
Conclusion 
Peripheral arterial disease is increasing in prevalence worid-wide and subsequently ischemia-induced wounds are increasing as well. Currently, management of 
risk factors and restoration of blood now to the is chemic limb are the standards of care. While work continues to improve our current surgical therapies some of 
the most exciting research is to promote angiogenesis in ischemic tissues through cell, gene and miRNA therapies. To help administer the new therapies as 
they become available and to give the optimal outcomes for these patients a multi-specialty team focused on ischemic limb wounds must be utilized. 
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